{"id":"https://openalex.org/W2890956843","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.e18096","title":"New and emerging therapies for relapse/refractory multiple myeloma: Impact of education on practice behaviors.","display_name":"New and emerging therapies for relapse/refractory multiple myeloma: Impact of education on practice behaviors.","publication_year":2017,"publication_date":"2017-05-20","ids":{"openalex":"https://openalex.org/W2890956843","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.e18096","mag":"2890956843"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2017.35.15_suppl.e18096","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.e18096","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2017.35.15_suppl.e18096","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5035619191","display_name":"Anne C. Roc","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anne Roc","raw_affiliation_strings":["PlatformQ Health, LLC, Needham, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PlatformQ Health, LLC, Needham, MA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063703288","display_name":"Wendy Turell","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wendy Turell","raw_affiliation_strings":["PlatformQ Health, LLC, Needham, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PlatformQ Health, LLC, Needham, MA;","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5007747233","display_name":"David Dingli","orcid":"https://orcid.org/0000-0001-7477-3004","observed_orcids":["https://orcid.org/0000-0001-7477-3004"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Dingli","raw_affiliation_strings":["Mayo Clinic, Rochester, MN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Rochester, MN;","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"35","issue":"15_suppl","first_page":"e18096","last_page":"e18096"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.7304999828338623,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.7304999828338623,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10254","display_name":"Innovations in Medical Education","score":0.2506999969482422,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13946","display_name":"Musculoskeletal Disorders and Rehabilitation","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2742","display_name":"Rehabilitation"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/novel-therapies","display_name":"new drugs","score":0.9179999828338623},{"id":"https://openalex.org/keywords/continuing-medical-education","display_name":"continuing medical education","score":0.7749999761581421},{"id":"https://openalex.org/keywords/physician-practice-behavior","display_name":"physician practice behavior","score":0.6359999775886536},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.8169999718666077},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.984000027179718},{"id":"https://openalex.org/keywords/histone-deacetylase-inhibitors","display_name":"histone deacetylase inhibitors","score":0.8769999742507935},{"id":"https://openalex.org/keywords/daratumumab","display_name":"daratumumab","score":0.9760000109672546},{"id":"https://openalex.org/keywords/elotuzumab","display_name":"elotuzumab","score":1.0},{"id":"https://openalex.org/keywords/selinexor","display_name":"selinexor","score":0.9980000257492065},{"id":"https://openalex.org/keywords/biochemical-progression","display_name":"biochemical progression","score":0.5600000023841858}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8661143779754639},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.635726809501648},{"id":"https://openalex.org/C100521375","wikidata":"https://www.wikidata.org/wiki/Q2015382","display_name":"Competence (human resources)","level":2,"score":0.5336772799491882},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.4131090044975281},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.41226649284362793},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.39485660195350647},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.37644827365875244},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.36753982305526733},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.28175193071365356},{"id":"https://openalex.org/C77805123","wikidata":"https://www.wikidata.org/wiki/Q161272","display_name":"Social psychology","level":1,"score":0.0},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2017.35.15_suppl.e18096","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.e18096","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2017.35.15_suppl.e18096","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4399480818","https://openalex.org/W2586154278","https://openalex.org/W4405048516","https://openalex.org/W3215488746","https://openalex.org/W4400272303","https://openalex.org/W4405045928","https://openalex.org/W4417012663","https://openalex.org/W4310163438","https://openalex.org/W2953346819","https://openalex.org/W4387003843"],"abstract_inverted_index":{"e18096":[0],"Background:":[1],"Newly":[2],"approved":[3],"and":[4,28,35,47,54,75,82,100,111,136,157,166,190,225,252,261,265,293,297,303],"emerging":[5,48,160,266],"agents":[6,161,165],"with":[7,18,72,171,175,249,275],"novel":[8],"mechanisms":[9],"of":[10,26,63,117,125,159,182,203,206,258,273,283],"action":[11],"present":[12],"unique":[13],"challenges":[14],"to":[15,59,106,211,269],"treating":[16],"patients":[17,194,274],"relapsed/refractory":[19],"multiple":[20],"myeloma":[21],"(RRMM),":[22],"including":[23],"keeping":[24],"abreast":[25],"rapid":[27],"ever-aggregating":[29],"data":[30],"on":[31,45,255,289],"their":[32,142,150,167],"safety,":[33],"tolerability":[34],"efficacy.":[36],"To":[37],"address":[38],"these":[39],"challenges,":[40],"an":[41],"education":[42,113,288],"activity":[43,129],"focused":[44],"new":[46],"therapies":[49,267],"for":[50,88,193,246],"RRMM":[51,290],"was":[52,78],"developed":[53],"learner":[55],"responses":[56,92],"were":[57,104],"evaluated":[58],"determine":[60],"the":[61,128,154,179,201,242,256,271,279,285],"impact":[62],"education.":[64],"Methods:":[65],"A":[66],"live-online":[67],"1-hour":[68],"video":[69],"panel":[70],"discussion":[71],"slides,":[73],"polling,":[74],"live":[76,101],"questions":[77,102],"produced":[79],"in":[80,149,213,300],"2016":[81],"made":[83],"available":[84,164],"on-demand":[85],"at":[86],"OMedLive.com":[87],"6":[89],"months.":[90],"Survey":[91],"(pre-,":[93],"post-,":[94],"8":[95],"weeks":[96],"post-activity),":[97],"polling":[98],"responses,":[99],"asked":[103],"tracked":[105],"measure":[107],"engagement,":[108],"lessons":[109],"learned,":[110],"additional":[112],"gaps.":[114],"Results:":[115],"51":[116],"288":[118,207],"learners":[119,146,208],"completed":[120],"all":[121],"pre/post/follow-up":[122],"surveys,":[123],"67%":[124],"which":[126,239],"reported":[127,138,147,209],"positively":[130,140],"impacted":[131,141],"patient":[132,226,248],"experience":[133],"or":[134],"outcome":[135],"61%":[137],"it":[139],"clinical":[143,227],"practice.":[144],"These":[145],"improvements":[148],"ability":[151],"to:":[152,215],"assess":[153],"relative":[155,168],"safety":[156],"efficacy":[158,169],"(50%),":[162],"differentiate":[163],"(50%":[170],"proteasome":[172],"inhibitors,":[173],"39%":[174],"monoclonal":[176],"antibodies),":[177],"see":[178],"potential":[180],"benefit":[181],"HDAC":[183],"inhibitors":[184],"(35%),":[185],"use":[186],"combination":[187],"regimens":[188],"(29%),":[189],"adjust":[191],"treatments":[192],"who\u2019ve":[195],"experienced":[196],"disease":[197],"progression":[198],"(29%).":[199],"As":[200],"result":[202],"education,":[204],"95":[205],"commitments":[210],"change":[212],"regards":[214],"medical/practice":[216],"knowledge":[217,254],"(95%),":[218],"care":[219],"attitudes":[220],"(89%),":[221],"practice":[222],"behavior":[223],"(76%),":[224],"outcomes":[228],"(81%).":[229],"Learners":[230],"also":[231],"demonstrated":[232],"improved":[233,253],"competence":[234],"via":[235],"a":[236,247],"case":[237],"scenario":[238],"required":[240],"identifying":[241],"optimal":[243],"next":[244],"step":[245],"biochemical":[250],"progression,":[251],"characteristics":[257],"daratumumab,":[259],"elotuzumab,":[260],"selinexor.":[262],"Conclusions:":[263],"New":[264],"promise":[268],"improve":[270],"lives":[272],"RRMM,":[276],"but":[277],"complicates":[278],"already":[280],"difficult":[281],"task":[282],"managing":[284],"disease.":[286],"Ongoing":[287],"is":[291],"recommended":[292],"can":[294],"yield":[295],"immediate":[296],"sustained":[298],"gains":[299],"knowledge,":[301],"competence,":[302],"performance.":[304]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2018-09-27T00:00:00"}